Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy
Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 2...
Saved in:
Published in | Vaccines (Basel) Vol. 9; no. 11; p. 1354 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel
MDPI AG
18.11.2021
MDPI |
Subjects | |
Online Access | Get full text |
ISSN | 2076-393X 2076-393X |
DOI | 10.3390/vaccines9111354 |
Cover
Loading…
Abstract | Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55–3.72) for symptomatic infection and 2.66 (95% CI, 1.76–3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection. |
---|---|
AbstractList | Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55–3.72) for symptomatic infection and 2.66 (95% CI, 1.76–3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection. Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group ( p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55–3.72) for symptomatic infection and 2.66 (95% CI, 1.76–3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection. Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55-3.72) for symptomatic infection and 2.66 (95% CI, 1.76-3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection.Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55-3.72) for symptomatic infection and 2.66 (95% CI, 1.76-3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection. |
Author | Lovreglio, Piero Sallustio, Anna Loconsole, Daniela Stufano, Angela Campanella, Silvia Accogli, Marisa Morcavallo, Caterina Chironna, Maria Centrone, Francesca Peccarisi, Davide |
AuthorAffiliation | 2 Hygiene Unit, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy; annasallustio@libero.it 1 Department of Biomedical Sciences and Human Oncology-Hygiene Section, School of Medicine, University of Bari, 70124 Bari, Italy; daniela.loconsole@uniba.it (D.L.); francesca.centrone.fc@gmail.com (F.C.); caterinamorcavallo@gmail.com (C.M.); campanella.silvia@libero.it (S.C.); accoisa@gmail.com (M.A.); davidepec@libero.it (D.P.) 3 Interdisciplinary Department of Medicine-Section of Occupational Medicine, School of Medicine, University of Bari, 70124 Bari, Italy; angela.stufano@uniba.it (A.S.); piero.lovreglio@uniba.it (P.L.) |
AuthorAffiliation_xml | – name: 3 Interdisciplinary Department of Medicine-Section of Occupational Medicine, School of Medicine, University of Bari, 70124 Bari, Italy; angela.stufano@uniba.it (A.S.); piero.lovreglio@uniba.it (P.L.) – name: 2 Hygiene Unit, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy; annasallustio@libero.it – name: 1 Department of Biomedical Sciences and Human Oncology-Hygiene Section, School of Medicine, University of Bari, 70124 Bari, Italy; daniela.loconsole@uniba.it (D.L.); francesca.centrone.fc@gmail.com (F.C.); caterinamorcavallo@gmail.com (C.M.); campanella.silvia@libero.it (S.C.); accoisa@gmail.com (M.A.); davidepec@libero.it (D.P.) |
Author_xml | – sequence: 1 givenname: Daniela orcidid: 0000-0003-2057-9745 surname: Loconsole fullname: Loconsole, Daniela – sequence: 2 givenname: Francesca orcidid: 0000-0003-3018-5408 surname: Centrone fullname: Centrone, Francesca – sequence: 3 givenname: Caterina orcidid: 0000-0002-9145-503X surname: Morcavallo fullname: Morcavallo, Caterina – sequence: 4 givenname: Silvia orcidid: 0000-0002-6106-6471 surname: Campanella fullname: Campanella, Silvia – sequence: 5 givenname: Marisa surname: Accogli fullname: Accogli, Marisa – sequence: 6 givenname: Anna surname: Sallustio fullname: Sallustio, Anna – sequence: 7 givenname: Davide surname: Peccarisi fullname: Peccarisi, Davide – sequence: 8 givenname: Angela orcidid: 0000-0002-9101-7742 surname: Stufano fullname: Stufano, Angela – sequence: 9 givenname: Piero orcidid: 0000-0002-1609-9397 surname: Lovreglio fullname: Lovreglio, Piero – sequence: 10 givenname: Maria orcidid: 0000-0002-1043-1256 surname: Chironna fullname: Chironna, Maria |
BookMark | eNp1kk1vEzEQhleoiJbSM1dLXNrDpv5ar5cDUthSiFSpEoGImzXr9SaONnawvUX9GfxjNk2QaCR8sTXzzjMfntfZifPOZNlbgieMVfj6AbS2zsSKEMIK_iI7o7gUOavYj5N_3qfZRYxrPJ6KMCnKV9kp45IVVBZn2e96BW5p3RLdGkhDMBH5DtX3i9lNTqr3aHQH0MkEG5PVT86Z64xO1ruIftm0Qmll0Hz6dZ7XfpFTdGP6BOjy44RMBCkn9AqBa9G0364OVjIpr9ACggWXIrIOzf0wMoJDswT945vsZQd9NBeH-zz7fvvpW_0lv7v_PKund7nmgqeclkw2WJa4AdpQbsrSUGi45BJT0XaUFsLQTsuWFU0jO6E70TIqeGnGQfCGs_Nstue2HtZqG-wGwqPyYNWTwYelgjD23BulOwlYYl2QpuAtI9Bh3VAAwTQtyqoYWR_2rO3QbEyrjUsB-mfQ5x5nV2rpH5QUlEtRjYDLAyD4n4OJSW1s1KbvwRk_REUF5pgUku_qfnckXfshuHFUOxUl1TiBXUXFXqWDjzGYTmmbYPdrY37bK4LVbofU0Q6NcddHcX-b-F_EH8Dgx5k |
CitedBy_id | crossref_primary_10_3390_jcm11185442 crossref_primary_10_3390_microorganisms12040720 crossref_primary_10_1016_j_rmr_2023_09_005 crossref_primary_10_1002_mef2_70004 crossref_primary_10_3390_vaccines10091546 crossref_primary_10_22625_2072_6732_2024_16_3_45_55 crossref_primary_10_52589_AJBMR_IFNRHEKO crossref_primary_10_3390_vaccines10122172 crossref_primary_10_1080_23744235_2023_2232445 crossref_primary_10_2478_amb_2023_0014 crossref_primary_10_1002_adhm_202304575 crossref_primary_10_1016_j_cmi_2022_06_026 crossref_primary_10_1186_s42269_022_00825_w crossref_primary_10_58854_jicm_1247409 crossref_primary_10_1111_jebm_12465 crossref_primary_10_1155_2022_4838009 crossref_primary_10_2185_jjrm_71_101 crossref_primary_10_3390_biology12091267 crossref_primary_10_3892_etm_2022_11343 |
Cites_doi | 10.1056/NEJMoa2108891 10.1038/d41586-021-01696-3 10.1136/bmj.m4857 10.1136/bmj.n579 10.3390/microorganisms9071542 10.2807/1560-7917.ES.2021.26.26.2100557 10.1101/2021.03.24.21254277 10.1038/s41591-021-01397-4 10.2139/ssrn.3861566 10.1016/S0140-6736(21)02276-5 10.1016/j.cell.2021.06.020 10.1056/NEJMoa2114255 10.1016/S0140-6736(21)02183-8 10.1038/s41586-021-03426-1 10.1016/S0140-6736(21)01358-1 10.3390/ijerph18094766 10.1016/S0140-6736(21)01642-1 10.1001/jama.2021.14811 10.15585/mmwr.mm7036e1 10.1128/MRA.01487-20 |
ContentType | Journal Article |
Copyright | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 by the authors. 2021 |
Copyright_xml | – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 by the authors. 2021 |
DBID | AAYXX CITATION 3V. 7T7 7XB 8FD 8FE 8FH 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 GNUQQ GUQSH HCIFZ LK8 M2O M7P MBDVC P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM DOA |
DOI | 10.3390/vaccines9111354 |
DatabaseName | CrossRef ProQuest Central (Corporate) Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database ProQuest Central Student ProQuest Research Library SciTech Premium Collection Biological Sciences Research Library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
DatabaseTitle | CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology Public Health |
EISSN | 2076-393X |
ExternalDocumentID | oai_doaj_org_article_cf8a080c51b54d31af0cb2aa63c25795 PMC8624869 10_3390_vaccines9111354 |
GeographicLocations | Italy |
GeographicLocations_xml | – name: Italy |
GroupedDBID | 53G 5VS 8FE 8FH 8G5 AADQD AAHBH AAYXX ABUWG ADBBV AEUYN AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO GNUQQ GROUPED_DOAJ GUQSH HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM 3V. 7T7 7XB 8FD 8FK C1K FR3 MBDVC P64 PKEHL PQEST PQGLB PQUKI Q9U 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c464t-2738b0870ba2b24e77e2ab4848026df2256e2fc8d35bb8f6cf6d32647e0004b43 |
IEDL.DBID | M48 |
ISSN | 2076-393X |
IngestDate | Wed Aug 27 01:17:17 EDT 2025 Thu Aug 21 13:59:23 EDT 2025 Mon Jul 21 10:41:15 EDT 2025 Fri Jul 25 12:01:11 EDT 2025 Thu Apr 24 23:03:53 EDT 2025 Tue Jul 01 02:25:01 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c464t-2738b0870ba2b24e77e2ab4848026df2256e2fc8d35bb8f6cf6d32647e0004b43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-6106-6471 0000-0003-3018-5408 0000-0002-9101-7742 0000-0003-2057-9745 0000-0002-1043-1256 0000-0002-1609-9397 0000-0002-9145-503X |
OpenAccessLink | https://doaj.org/article/cf8a080c51b54d31af0cb2aa63c25795 |
PMID | 34835285 |
PQID | 2602194805 |
PQPubID | 2032320 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_cf8a080c51b54d31af0cb2aa63c25795 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8624869 proquest_miscellaneous_2604015844 proquest_journals_2602194805 crossref_citationtrail_10_3390_vaccines9111354 crossref_primary_10_3390_vaccines9111354 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20211118 |
PublicationDateYYYYMMDD | 2021-11-18 |
PublicationDate_xml | – month: 11 year: 2021 text: 20211118 day: 18 |
PublicationDecade | 2020 |
PublicationPlace | Basel |
PublicationPlace_xml | – name: Basel |
PublicationTitle | Vaccines (Basel) |
PublicationYear | 2021 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Malani (ref_19) 2021; 326 Singh (ref_27) 2021; 27 Tartof (ref_35) 2021; 398 ref_14 ref_13 ref_12 Siegel (ref_30) 2021; 70 ref_32 ref_31 Challen (ref_11) 2021; 372 Hill (ref_3) 2021; 6 Veneti (ref_17) 2021; 26 Andrews (ref_34) 2021; 385 ref_18 Sheikh (ref_16) 2021; 397 ref_39 Sonabend (ref_41) 2021; 398 ref_38 ref_15 Liu (ref_33) 2021; 184 Goldberg (ref_37) 2021; 385 ref_25 ref_24 ref_23 ref_22 ref_21 ref_20 ref_40 ref_1 Callaway (ref_28) 2021; 595 ref_2 ref_29 Wise (ref_4) 2020; 371 Shrotri (ref_36) 2021; 398 ref_9 Davies (ref_10) 2021; 593 ref_5 Loconsole (ref_8) 2021; 10 ref_7 Lustig (ref_26) 2021; 26 ref_6 |
References_xml | – volume: 385 start-page: 585 year: 2021 ident: ref_34 article-title: Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2108891 – ident: ref_5 – ident: ref_32 – ident: ref_24 – volume: 595 start-page: 17 year: 2021 ident: ref_28 article-title: Delta coronavirus variant: Scientists brace for impact publication-title: Nature doi: 10.1038/d41586-021-01696-3 – volume: 371 start-page: m4857 year: 2020 ident: ref_4 article-title: Covid-19: New coronavirus variant is identified in UK publication-title: BMJ. doi: 10.1136/bmj.m4857 – volume: 26 start-page: 2100793 year: 2021 ident: ref_17 article-title: Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021 publication-title: Euro. Surveill. – ident: ref_39 – ident: ref_40 – volume: 372 start-page: n579 year: 2021 ident: ref_11 article-title: Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study publication-title: BMJ doi: 10.1136/bmj.n579 – ident: ref_18 doi: 10.3390/microorganisms9071542 – volume: 26 start-page: 2100557 year: 2021 ident: ref_26 article-title: Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel publication-title: Euro. Surveill. doi: 10.2807/1560-7917.ES.2021.26.26.2100557 – ident: ref_14 – ident: ref_1 – ident: ref_23 – ident: ref_21 – ident: ref_7 doi: 10.1101/2021.03.24.21254277 – volume: 27 start-page: 1131 year: 2021 ident: ref_27 article-title: SARS-CoV-2 variants of concern are emerging in India publication-title: Nat. Med. doi: 10.1038/s41591-021-01397-4 – ident: ref_6 – ident: ref_15 doi: 10.2139/ssrn.3861566 – ident: ref_25 – ident: ref_31 – volume: 398 start-page: 1825 year: 2021 ident: ref_41 article-title: Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: A mathematical modelling study publication-title: Lancet doi: 10.1016/S0140-6736(21)02276-5 – volume: 6 start-page: 121 year: 2021 ident: ref_3 article-title: Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch publication-title: Wellcome Open Res. – ident: ref_29 – ident: ref_2 – volume: 184 start-page: 4220 year: 2021 ident: ref_33 article-title: Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum publication-title: Cell doi: 10.1016/j.cell.2021.06.020 – ident: ref_12 – volume: 385 start-page: 1393 year: 2021 ident: ref_37 article-title: Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2114255 – volume: 398 start-page: 1407 year: 2021 ident: ref_35 article-title: Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(21)02183-8 – ident: ref_13 – ident: ref_38 – volume: 593 start-page: 270 year: 2021 ident: ref_10 article-title: Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 publication-title: Nature doi: 10.1038/s41586-021-03426-1 – volume: 397 start-page: 2461 year: 2021 ident: ref_16 article-title: Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness publication-title: Lancet doi: 10.1016/S0140-6736(21)01358-1 – ident: ref_9 doi: 10.3390/ijerph18094766 – volume: 398 start-page: 385 year: 2021 ident: ref_36 article-title: Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 publication-title: Lancet doi: 10.1016/S0140-6736(21)01642-1 – ident: ref_22 – ident: ref_20 – volume: 326 start-page: 1001 year: 2021 ident: ref_19 article-title: Confronting the Delta Variant of SARS-CoV-2, Summer 2021 publication-title: JAMA doi: 10.1001/jama.2021.14811 – volume: 70 start-page: 1249 year: 2021 ident: ref_30 article-title: Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0-17 Years—United States, August 2020–August 2021 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7036e1 – volume: 10 start-page: e01487-20 year: 2021 ident: ref_8 article-title: Genome Sequence of a SARS-CoV-2 VUI 202012/01 Strain Identified from a Patient Returning from London, England, to the Apulia Region of Italy publication-title: Microbiol. Resour. Announc. doi: 10.1128/MRA.01487-20 |
SSID | ssj0000913867 |
Score | 2.255769 |
Snippet | Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1354 |
SubjectTerms | Contact tracing Coronaviruses COVID-19 COVID-19 vaccine COVID-19 vaccines Demographics Disease control Disease transmission Epidemiology Health surveillance Hospitalization Immunization Infections Laboratories Patients Public health Respiratory diseases SARS-CoV-2 Alpha variant SARS-CoV-2 Delta variant Severe acute respiratory syndrome coronavirus 2 Statistical analysis surveillance Vaccination Virulence |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1da9swFBWjT3sZ-2TZunIHo7RQu9GHZXlvabrSDLaVtQ19M5IssUJRRpMU8jP2j3clu2k8GHvZqyUbWbpXOke694iQD76yeliZInM-7lZxqzKDOCErpW1oYVSpUn7Fl6_y9FJ8viquNq76ijFhrTxw23GH1iuNqMYW1BSi4VT7oTVMa8ktWluV1EtxzdsgU2kOrihXsmy1fDjy-sM7beNJ9Tw6Ny9EbxlKav09iNkPkNxYcU6ekicdVIRR28Rn5JELz8nuWas1vTqAi4fUqfkB7MLZgwr16gX5lfIGcGGCiPKWyKph5mH8bTo5zmj1EcZ9peZYOOkCs8Ic4vYsIDaE89H382w8m2YMjt3NQsPeUU5zBCQ52wcdGhjFZN32Kc3LfZgi-Y6xNXAdIN3P524DTBDir16Sy5NPF-PTrLt_IbNCikXK2jFDdGijmWHClaVj2gglFBK3xuNMIB3zVjW8MEZ5ab1sEA2K0kWkaAR_RbbCLLjXBLxnMeqqkMiuBNei4kYZQRnVilP8xoDk98NR206cPN6RcVMjSYnjV_8xfgOyt37hZ6vL8feqR3F819WioHZ6gGZWd2ZW_8vMBmT73jrqzsvnNXJBnPCxO7D4_boY_TMeuujgZstUBykswjxsR9mzql6D-iXh-kdS-o7ZO0pWb_7HH7wlj1mMx4khjGqbbC1ul-4dAqqF2Um-8xs9NB3i priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwELZg-4KEEAwQhYEOCU2btHSN4zgOX1DbbVqRGNVeqn2LbMeGSVMy-oLUn8E_5i5JW4IEX2MnsXS-83Pnu-cY--BTq3upiQPnKVoVWRUYxAlBIm0exkYlqqqv-HIuz67F55v4pgm4zZq0ypVNrAx1XlqKkR8h7kblEqoXf7r_EVDXKLpdbVpoPGTbaIIV7vDtwcn5-GIdZSHWSyWTmtMnQv_-6Ke2dGM9IyWPYtE6jirW_hbUbCdK_nHynD5lTxrICP1axs_YA1fssL1xzTm9PISrTQnV7BD2YLxho17usMd1YA7qeqPn7FdVT4AHFhD6W6C3DaWH4dfJ6DgI048wbDM40-CoSdgqZkBhW0DMCJf9i8tgWE4CDsfubq5hf9ANuwhUuvwAdJFDn4p466dhNzmACTrllHMDtwVUffvctIARQv_lC3Z9enI1PAuavgyBFVLMq2oe00NFN5obLlySOK6NUCgcLnOPFkI67q3Ko9gY5aX1MkeUKBJHCNKI6CXbKsrCvWLgPadsrFii1yUiLdLIKCNCHmoVhfiNDuuuxJPZhrScemfcZei8kDyzv-TZYfvrF-5rvo5_Tx2QvNfTiGi7elBOv2WN3mbWK42g2sahiUUehdr3rOFay8iisUvjDttd7Zas0f5ZttmrHfZ-PYx6S5cxunDlopqDri3CP1xH0tplrQW1R4rb7xUDOFX1KJm-_v_P37BHnDJwKGlR7bKt-XTh3iKEmpt3jZ78Bp6WG2E priority: 102 providerName: ProQuest |
Title | Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy |
URI | https://www.proquest.com/docview/2602194805 https://www.proquest.com/docview/2604015844 https://pubmed.ncbi.nlm.nih.gov/PMC8624869 https://doaj.org/article/cf8a080c51b54d31af0cb2aa63c25795 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZge-EFjZsojMpIaNqkJTS2kzhICLXdphVpo9rWqm-R7dgwqUpHL4j-DP4x57hpS9CQeLWdyPHx8fk-51wIeecyo1qZjgPr8LaKGxlowAlBmpgiirVMpY-vuLhMzgfi8ygebcsBVQs4u5faYT2pwXQc_vy-_AQK_xEZJ1D29z-UwZ_QM9RbHouHZBfMUop1HC4qrO-P5Szi0leUZcDdA57x0SrVz33vqFkpn8y_hkDr_pN_GKSzPfK4QpK0vRL9E_LAlk_JQX-Vinp5TG-2kVWzY3pA-9sk1ctn5JcPKwC7RREELoB004mj3S_D3kkQZR9ot57IGTt7ld9WOaN4e0sBOtLr9tV10J0MA0ZP7Hiu6GEnjELAKyE7oqosaBtjeVetUZge0SFwc3S9obcl9eX77LSkPVj85XMyODu96Z4HVXmGwIhEzH1Qj26BvmvFNBM2TS1TWkghgdcVDg6KxDJnZMFjraVLjEsKAIsitQgkteAvyE45Ke1LQp1j6JQVJ0C-BFci41pqEbFISR7BOxokXIsjN1XuciyhMc6Bw6D88r_k1yCHmwfuVmk7_j20g_LdDMN8275hMv2aV-qbGycVYGsTRzoWBY-UaxnNlEq4gTMvixtkf7078vUezoEqgj2A5YDut5tuUF_8J6NKO1n4McBwAQXCPNLarqpNqN5T3n7zicAxuEcm2av__9jX5BFDpxz0Y5T7ZGc-Xdg3gKrmukl2O6eX_aumv5Voet35DTVtIdM |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZG9wASQjBAKxtgJJg2aeka23EcJIR62dSyrVRbV-0t2I7DJk3JaFpQfwZ_hN_IcZK2BAne9mo7jqVz8XeOzwWht3GgZTNQnmNi662iWjgKcILjcx25nhK-yPMrTge8d8E-XXqXa-jXIhfGhlUudGKuqKNUWx_5AeBuEC4mmt7H22-O7RplX1cXLTQKtjg28x9gsmUf-l2g7ztCjg5HnZ5TdhVwNONsmueiqCawqZJEEWZ83xCpmICtCY9i4G9uSKxFRD2lRMx1zCPAOMw3Fv8oRmHfe2idUYAKNbTePhwMz5ZeHVtlU3C_qCFEadA8-C61fSHPrFKhHqtcf3mXgAq0rQZm_nHTHT1Gj0qIilsFTz1BaybZQDvDosb1fB-PVilb2T7ewcNV9ev5BnpYOAJxkd_0FP3M8xfggsQWbc7AusdpjDufx_2u4wbvcadaMdpO9ssAsSTD1k2MAaPi89bZudNJxw7BXXMzlXi33XAbAIwaZA_LJMItmzRcjLoNfw-PJYhWMs3wdYLzPoFmkuA-mBrzZ-jiTij2HNWSNDGbCMcxsdFfHgcrj1HJAqqEYi5xpaAu7FFHjQV5Ql0WSbe9Om5CMJYsPcO_6FlHu8sPbov6IP9e2rb0Xi6zhb3zgXTyNSz1RKhjIQHEa89VHouoK-OmVkRKTjUo18Cro-0Ft4SltsnClWzU0ZvlNOgJ-_gjE5PO8jVgSgPchHP4FS6rHKg6k1xf5RXHbRaR4MGL___8NbrfG52ehCf9wfEWekBs9I8NmBTbqDadzMxLgG9T9aqUGYy-3LWY_gZ6c1c2 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyEkhGCAVhhgJJg2aWkbx0kcJIR6WbUyKNUu1d6C7dgwaUpGL6D-DP4Ov45zkrQlSPC2V9uxI52Lv3N8LoS8spGWrUj5jrHorfK0cBTgBCcMdOL6SoQiz6_4OAyOzvn7C_9ig_xa5sJgWOVSJ-aKOsk0-sibgLtBuLho-U1bhkWMev13198c7CCFL63LdhoFixybxQ8w36ZvBz2g9WvG-odn3SOn7DDgaB7wWZ6XolrAskoyxbgJQ8Ok4gKOYUFigdcDw6wWiecrJWygbZAA3uGhQSykuAf73iKbIaaP1shm53A4Oll5eLDipgjCop6Q50Wt5nep8bV8igrG83nlKsw7BlRgbjVI849br3-f3CvhKm0X_PWAbJh0i-yOinrXiwN6tk7fmh7QXTpaV8JebJG7hVOQFrlOD8nPPJcBLkuKyHMOlj7NLO1-Gg96jhu9od1q9WicHJTBYumUosuYAl6lp-2TU6ebjR1Ge-ZqJulep-E2ACQ12D6VaULbmEBcjLqNcJ-OJYhZOpvSy5TmPQPNJKUDMDsWj8j5jVDsMamlWWq2CbWWYSSYH4DFxz3JI08JxV3mSuG5sEedNJbkiXVZMB37dlzFYDghPeO_6Fkne6sProtaIf9e2kF6r5Zhke98IJt8iUudEWsrJAB67bvK54nnStvSikkZeBoUbeTXyc6SW-JS80zjtZzUycvVNOgMfAiSqcnm-RowqwF6wn-EFS6r_FB1Jr38mlcfx4wiEURP_n_4C3IbxDP-MBgePyV3GAYCYeyk2CG12WRungGSm6nnpchQ8vmmpfQ3nqhbdA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changing+Features+of+COVID-19%3A+Characteristics+of+Infections+with+the+SARS-CoV-2+Delta+%28B.1.617.2%29+and+Alpha+%28B.1.1.7%29+Variants+in+Southern+Italy&rft.jtitle=Vaccines+%28Basel%29&rft.au=Loconsole%2C+Daniela&rft.au=Centrone%2C+Francesca&rft.au=Morcavallo%2C+Caterina&rft.au=Campanella%2C+Silvia&rft.date=2021-11-18&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=9&rft.issue=11&rft.spage=1354&rft_id=info:doi/10.3390%2Fvaccines9111354&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines9111354 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon |